- Home
- AARD vs III Comparison
AARD vs III Comparison
Compare AARD & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- III
- Stock Information
- Founded
- AARD 2017
- III 2006
- Country
- AARD United States
- III United States
- Employees
- AARD N/A
- III N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- III Professional Services
- Sector
- AARD Health Care
- III Consumer Discretionary
- Exchange
- AARD Nasdaq
- III Nasdaq
- Market Cap
- AARD 277.9M
- III 249.2M
- IPO Year
- AARD 2025
- III 2007
- Fundamental
- Price
- AARD $11.22
- III $5.68
- Analyst Decision
- AARD Strong Buy
- III Buy
- Analyst Count
- AARD 7
- III 1
- Target Price
- AARD $31.43
- III $5.50
- AVG Volume (30 Days)
- AARD 151.9K
- III 216.8K
- Earning Date
- AARD 11-14-2025
- III 11-03-2025
- Dividend Yield
- AARD N/A
- III 3.17%
- EPS Growth
- AARD N/A
- III N/A
- EPS
- AARD N/A
- III 0.16
- Revenue
- AARD N/A
- III $240,201,000.00
- Revenue This Year
- AARD N/A
- III N/A
- Revenue Next Year
- AARD N/A
- III $4.84
- P/E Ratio
- AARD N/A
- III $36.19
- Revenue Growth
- AARD N/A
- III N/A
- 52 Week Low
- AARD $4.88
- III $2.95
- 52 Week High
- AARD $19.58
- III $6.01
- Technical
- Relative Strength Index (RSI)
- AARD 39.08
- III 56.36
- Support Level
- AARD $10.65
- III $5.41
- Resistance Level
- AARD $17.94
- III $5.69
- Average True Range (ATR)
- AARD 0.95
- III 0.18
- MACD
- AARD -0.64
- III -0.01
- Stochastic Oscillator
- AARD 7.82
- III 91.67
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.